Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)

Patent metadata

Field	Value
Publication number	US-9896731-B2
Application number	US-201414171419-A
Country	US
Kind code	B2
Filing date	Feb 3, 2014
Priority date	May 11, 2009
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.

First claim

The invention claimed is:

1. A method for treating or preventing a skin oncological disorder in a human, wherein the skin oncological disorder is basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), the method comprising: topically administering a pharmaceutical composition comprising about 3% Coenzyme Q10 (CoQ10) to a target tissue of the human at a dose in the range of 0.1 to 0.5 milligrams of CoQ10 per square centimeter of skin such that treatment or prevention occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration of the composition to the subject results in an increase of CoQ10 in the oxidized form in the subject.

2. The method of claim 1 , wherein CoQ10 induces apoptosis or cell death mechanism in a cancerous cell of the oncological disorder.

3. The method of claim 1 , wherein CoQ10 inhibits angiogenesis in a tumor of the oncological disorder.

4. The method of claim 1 , wherein CoQ10 induces a modulation of immune-related elements within the microenvironment of a cancerous cell of the oncological disorder.

5. The method of claim 1 , wherein CoQ10 induces a change in cell cycle control in a cancerous cell of the oncological disorder.

6. The method of claim 1 , wherein a population of humans are treated and at least 25% of the population experiences a diminishment of symptoms as measured by art-recognized endpoints including tissue pathology, clinical observations, photographic analyses, CT-scan, MRI imaging, blood, serum, or plasma markers of cancer.

7. The method of claim 1 , wherein a population of humans are treated and at least 25% of the population had a systemic Coenzyme Q10 level that was therapeutic for the disorder being treated.

8. The method of claim 1 , wherein the concentration of Coenzyme Q10 in the tissues of the humans being treated is different than that of a control standard of human tissue representative of a healthy or normal state.

9. The method of claim 1 , wherein the treatment occurs via an interaction of Coenzyme Q10 with a protein selected from the group consisting of HNF4-alpha, Bcl-xl, Bcl-xS, BNIP-2, Bcl-2, Birch, Bcl-2-L11 (Bim), XIAP, BRAF, Bax, c-Jun, Bmf, PUMA, cMyc, transaldolase 1, COQ1, COQ3, COQ6, prenyltransferase, 4-hydrobenzoate, neutrophil cytosolic factor 2, nitric oxide synthase 2A, superoxide dismutase 2, VDAC, Bax channel, ANT, Cytochrome c, complex 1, complex II, complex III, complex IV, Foxo 3a, DJ-1, IDH-1, Cpt1C, and Cam Kinase II and any one or more of genes listed in Tables 2-4 & 6-28.

10. The method of claim 1 , wherein Coenzyme Q10 is applied in a topical vehicle to a target tissue at a dose of about 0.12 milligrams of coenzyme Q10 per square centimeter of skin.

11. The method of claim 1 , wherein the oncological disorder is Squamous cell Carcinoma.

12. The method of claim 1 , wherein the oncological disorder is Basal Cell Carcinoma.

13. The method of claim 1 , wherein the oncological disorder is SCC, and wherein the method prevents the pre-cancerous lesion actinic keratosis from progressing into SCC.

14. The method of claim 1 , wherein the composition comprising Coenzyme Q10 is topically applied one or more times per 24 hours for six weeks or more.

15. The method of claim 1 , wherein the composition comprising Coenzyme Q10 is administered in the form of a CoQ10 cream.

16. The method of claim 1 , further comprising an additional treatment regimen selected from the group consisting of surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, therapy with cytokines, and chemotherapy.

17. The method of claim 1 , wherein the pharmaceutical composition comprises a CoQ10 cream comprising:
(1) a phase A having Capric/Caprylictriglyceride at 4.00% w/w of the composition, cetyl alcohol at 2.00% w/w of the composition, stearyl alcohol at 1.5% w/w, glyceryl stearate and PEG-100 at 4.5% w/w;
(2) a phase B having glycerin at 2.00% w/w, propylene glycol at 1.5% w/w, ethoxydiglycol at 5.0% w/w, phenoxyethanol at 0.475% w/w, a carbomer dispersion at 40.00% w/w, purified water at 16.725% w/w;
(3) a phase C having triethanolamine at 1.300% w/w, lactic acid at 0.500% w/w, sodium lactate solution at 2.000% w/w, water at 2.5% w/w;
(4) a phase D having titanium dioxide at 1.000% w/w; and
(5) a phase E having CoQ10 21% concentrate at 15.000% w/w.

18. The method of claim 17 , wherein the carbomer dispersion comprises water, phenoxyethanol and propylene glycol.

Assignees

• Berg Llc

Inventors

• Narain Niven Rajin
• Mccook John Patrick

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title